The Effect of Canakinumab Treatment on the Inflammatory Markers in Children with Colchicine-Resistant Familial Mediterranean Fever

Objectives: This study aimed to determine the reliability of novel markers of treatment response in children with familial Mediterranean fever receiving canakinumab treatment, as compared to conventional inflammatory indexes Methods: Clinical and laboratory data for 19 colchicine-resistant Familial Mediterranean Fever patients treated with canakinumab were retrospectively reviewed. Patients with systemic diseases other than familial Mediterranean fever and familial Mediterranean fever related complications were excluded from the study. Results: Following canakinumab treatment there was a non-significant decrease in the neutrophil/ lymphocyte ratio (P = 0.523) and a significant decrease in the platelet/lymphocyte ratio (P = 0.003). There wasn no significant difference in mean platelet volume before and after canakinumab treatment (P = 0.762). Conclusions: The present findings indicate that the platelet/lymphocyte ratio could be considered a more reliable marker than the neutrophil/lymphocyte ratio of response to canakinumab therapy in patients with colchicine-resistant familial Mediterranean

[1]  S. Ozen,et al.  Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. , 2017, Seminars in arthritis and rheumatism.

[2]  N. Çakar,et al.  Assessment of neutrophil to lymphocyte ratio and mean platelet volume in pediatric familial Mediterranean fever patients , 2017, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[3]  P. Hashkes,et al.  Canakinumab investigated for treating familial Mediterranean fever , 2016, Expert opinion on biological therapy.

[4]  D. Mikhailidis,et al.  The Relation Between Atherosclerosis and the Neutrophil–Lymphocyte Ratio , 2016, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[5]  M. La Regina,et al.  Autoinflammatory diseases: a possible cause of thrombosis? , 2015, Thrombosis Journal.

[6]  D. Karabel,et al.  Assessment of epicardial adipose tissue thickness and the mean platelet volume in children with familial Mediterranean fever , 2015, Italian Journal of Pediatrics.

[7]  E. Sönmezgöz,et al.  Simple Markers for Subclinical Inflammation in Patients with Familial Mediterranean Fever , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[8]  G. Zararsiz,et al.  Neutrophil–Lymphocyte Ratio in Patients With Familial Mediterranean Fever , 2015, Journal of clinical laboratory analysis.

[9]  D. Karabel,et al.  Usefulness of Mean Platelet Volume and Neutrophil-to-Lymphocyte Ratio for Evaluation of Children with Familial Mediterranean Fever , 2014, Medical science monitor : international medical journal of experimental and clinical research.

[10]  I. Tannock,et al.  Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[11]  S. Ozen,et al.  A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin , 2014, Nature Reviews Rheumatology.

[12]  P. Portincasa,et al.  Novel Therapeutics for the Treatment of Familial Mediterranean Fever: From Colchicine to Biologics , 2013, Clinical pharmacology and therapeutics.

[13]  A. Agudo,et al.  Iron and Cancer Risk—A Systematic Review and Meta-analysis of the Epidemiological Evidence , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[14]  M. Uysal,et al.  As a New Inflammatory Marker for Familial Mediterranean Fever: Neutrophil-to-Lymphocyte Ratio , 2013, Inflammation.

[15]  K. Deveci,et al.  Is Neutrophil/Lymphocyte Ratio Associated with Subclinical Inflammation and Amyloidosis in Patients with Familial Mediterranean Fever? , 2013, BioMed research international.

[16]  Öznur Kal,et al.  Mean platelet volume as a potential predictor of proteinuria and amyloidosis in familial Mediterranean fever , 2013, Clinical Rheumatology.

[17]  Ş. Şahin,et al.  Does mean platelet volume influence the attack or attack-free period in the patients with Familial Mediterranean fever? , 2013, Platelets.

[18]  N. Yazıhan,et al.  Relationship of paraoxonase-1, malondialdehyde and mean platelet volume with markers of atherosclerosis in familial Mediterranean fever: an observational study. , 2013, Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology.

[19]  K. Aksu,et al.  Inflammation-induced thrombosis: mechanisms, disease associations and management. , 2012, Current pharmaceutical design.

[20]  A. Kızıltunç,et al.  Relationship between serum interleukin–1β levels and acute phase response proteins in patients with familial Mediterranean fever , 2012, Biochemia medica.

[21]  T. Çelik,et al.  Evaluation of the mean platelet volume in children with familial Mediterranean fever , 2012, Rheumatology International.

[22]  S. Ozen,et al.  Renal amyloidosis in children , 2011, Pediatric Nephrology.

[23]  I. Ben-Zvi,et al.  Chronic inflammation in FMF: markers, risk factors, outcomes and therapy , 2011, Nature Reviews Rheumatology.

[24]  G. Kitas,et al.  Mean platelet volume: a link between thrombosis and inflammation? , 2011, Current pharmaceutical design.

[25]  I. Dursun,et al.  Are mean platelet volume and splenomegaly subclinical inflammatory marker in children with familial mediterranean fever , 2010 .

[26]  B. Makay,et al.  Mean platelet volume in children with familial Mediterranean fever , 2009, Clinical Rheumatology.

[27]  T. Molina,et al.  Gene Expression Profile Analysis According to Recurrent Gene Copy Number Abnormalities Defines a Diffuse Large B-Cell Lymphoma Subgroup Characterized by 9p21 Locus Deletion, Ribosome Machinery Deregulation and Poor Prognosis. A GELA Study , 2008 .

[28]  D. Kastner,et al.  The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. , 2008, Blood.

[29]  A. Ozkan,et al.  Is Familial Mediterranean Fever a thrombotic disease or not? , 2008, European Journal of Pediatrics.

[30]  Chi-kong Li,et al.  Interleukin-1beta up-regulates the expression of thrombopoietin and transcription factors c-Jun, c-Fos, GATA-1, and NF-E2 in megakaryocytic cells. , 2004, The Journal of laboratory and clinical medicine.

[31]  M. Pras,et al.  Neutrophil Adhesion Molecule Expression in Familial Mediterranean Fever: Discordance between the Intravascular Regulation of β2 Integrin and L-Selectin Expression in Acute Attack , 2004, Journal of Investigative Medicine.

[32]  C. Esmon.  Inflammation and thrombosis , 2003, Journal of thrombosis and haemostasis : JTH.

[33]  Chi-kong Li,et al.  Expression of interleukin (IL) 1 type I and type II receptors in megakaryocytic cells and enhancing effects of IL-1beta on megakaryocytopoiesis and NF-E2 expression. , 2000, British journal of haematology.

[34]  D. Mikhailidis,et al.  Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. , 2000, Platelets.

[35]  E. Ben-Chetrit,et al.  Colchicine: 1998 update. , 1998, Seminars in arthritis and rheumatism.

[36]  C. Berul,et al.  Effects of cocaine hydrochloride on the male reproductive system. , 1989, Life sciences.

[37]  Y. Hirai,et al.  Interleukin-1 potentiates granulopoiesis and thrombopoiesis by producing hematopoietic factors in vivo. , 1989, Life sciences.

[38]  Thompson Cb,et al.  From precursor to product: how do megakaryocytes produce platelets? , 1986, Progress in clinical and biological research.

[39]  C. Thompson.  From precursor to product: how do megakaryocytes produce platelets? , 1986, Progress in clinical and biological research.